Indeed, as outlined in previous sections, especially for neurological diseases more selective approaches are warranted as there is a clear discrepancy between TNFR1 and TNFR2 signaling in the brain typified by the aggravated disease symptoms that are induced by anti-TNF drugs in MS patients. This evidence concerns the gene TNF and nervous system disorder.